In this segment, Cagney Cristancho, MD, outlines why non-incretin pharmacologic options remain essential in obesity care despite the rapid expansion of incretin-based therapies.
Back
Weight-Loss Pharmacotherapy Beyond Incretins: Patient Selection, Safety, and Real-World Decision-Making
Dr Cagney Cristancho emphasizes that non-incretin obesity medications remain essential due to real-world access and patient-specific factors, and should be used through individualized selection, safety monitoring, and long-term chronic disease management.
Weight-Loss Pharmacotherapy Beyond Incretins: Patient Selection, Safety, and Real-World Decision-Making
Episodes
All
All
Dr Cristancho describes how patient goals, time horizon, and clinical drivers of obesity guide the selection and counseling of non-incretin weight loss medications.
Dr Cristancho reviews the targeted role of sympathomimetic agents and outlines essential cardiovascular, psychiatric, and drug–drug interaction assessments before initiating non-incretin medications.
In this segment, Dr Cristancho describes a pragmatic follow-up schedule and objective criteria—including early weight-loss benchmarks—to determine whether to continue, adjust, or discontinue non-incretin treatment.
Dr Cristancho explains how to sequence or switch among non-incretin agents and how to reframe pharmacotherapy as part of long-term, chronic disease management rather than short-term weight loss.
Dr Cristancho addresses how regulatory constraints and educational gaps affect real-world use of non-incretin agents and highlights the need for practical, guidance-based training.
Advertisement
Advertisement
Trending on HCPLive
1
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
2
Culprits in Perioperative Allergy, With Kimberly Blumenthal, MD
3
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
4
Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD
5